OMCL

Omnicell, Inc. 10-Q Summary: Period Ended June 30, 2007

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for Omnicell, Inc., a provider of medication and supply dispensing systems for the healthcare industry. The report covers the three and six-month periods ended June 30, 2007. The company operates as a single reportable segment, with substantially all revenues generated in the United States.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 42.9% for the three months and 42.0% for the six months ended June 30, 2007, compared to the same periods in 2006. This was driven by increased unit volume of medication and supply automation systems.
• Net Income Surge: Net income for the six months ended June 30, 2007, was $22.1 million, a significant increase from $3.1 million in the prior year period. This was primarily due to a non-cash income tax benefit of $12.4 million resulting from the partial release of a valuation allowance on deferred tax assets.
• Gross Margin Compression: Gross margin declined slightly (3.0% for the quarter, 2.6% for the six months) due to a larger allocation of shared operating expenses to cost of revenues, lower sales of higher-margin lease renewals, and increased infrastructure costs.
• Liquidity Expansion: Cash and cash equivalents increased from $60.9 million at December 31, 2006, to $172.1 million at June 30, 2007. This increase was driven by operating cash flow and net proceeds of $90.2 million from a secondary public offering of common stock in May 2007.

Guidance, Outlook, and Risks

• Outlook: Management anticipates continued revenue growth driven by market demand for patient safety and automation. However, they do not anticipate the recent decline in gross margin to represent a long-term trend, though margins could fluctuate based on product mix and cost allocations.
• Internal Controls: The company disclosed a material weakness in internal controls over financial reporting as of December 31, 2006, related to the review of reconciliations and account balances. While remediation efforts were substantially complete as of June 30, 2007, testing by the independent auditor was not yet finished. Consequently, disclosure controls and procedures were deemed not effective as of the reporting date.
• Legal Proceedings: The company is a defendant in a product liability lawsuit (Alcala, et al. v. Cardinal Health, Inc., et al.) alleging that a defect in their product contributed to a patient's death. Omnicell denies liability and intends to defend vigorously.
• Market Risks: Key risks include intense competition, dependence on a single-source supplier for sub-assemblies, potential delays in customer installations affecting revenue recognition, and the need to manage rapid growth.

Investor Verification Checklist

• Tax Benefit Sustainability: Verify the sustainability of the $12.4 million tax benefit, which was a one-time adjustment from releasing a valuation allowance, and assess the remaining $24.9 million valuation allowance against deferred tax assets.
• Internal Control Remediation: Monitor the completion of testing for the remediated internal controls to ensure future financial reporting reliability and compliance with Sarbanes-Oxley Section 404.
• Gross Margin Trends: Track future gross margins to determine if the decline is temporary or indicative of structural cost increases or pricing pressure.
• Backlog Conversion: Assess the company's ability to convert the $131.4 million product backlog into recognized revenue, given the 6-9 month installation cycle.
• Supplier Concentration: Evaluate the risks associated with the single-source supplier for hardware sub-assemblies and the status of efforts to secure secondary manufacturing sites.